CARY, N.C., July 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. , a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets, announced today that David Price, Executive Vice President, Finance, and Chief Financial Officer, has been named Triangle Business Journal's CFO of the Year in the Small Public Business category. Award recipients were recognized at the inaugural Triangle Business Journal's CFO of the Year Awards Luncheon held in Cary on July 14, 2009.
Mr. Price joined Cornerstone Therapeutics as Executive Vice President, Finance, and Chief Financial Officer, in September 2008, just prior to the completion of the reverse merger between Critical Therapeutics, Inc. and Cornerstone BioPharma, Inc., a transaction he helped facilitate as managing director at Jefferies & Company, Inc. In addition, Mr. Price was instrumental in finalizing Cornerstone's recently announced agreement with Chiesi Farmaceutici, SpA, a leading European pharmaceutical company headquartered in Parma, Italy, that resulted in a $70 million transaction and Cornerstone's receipt of an exclusive 10-year license for the U.S. commercial rights to Curosurf(R), the world leading treatment approved by the U.S. Food and Drug Administration for Respiratory Distress Syndrome in premature infants.
About Cornerstone Therapeutics
Curosurf(R) is a registered trademark of Chiesi Farmaceutici, SpA.
SOURCE Cornerstone Therapeutics Inc.
CONTACT: Investor Relations Contacts: Evan Smith, evan.smith@fd.com, or
Brian Ritchie, brian.ritchie@fd.com, both of FD, +1-212-850-5600, Media
Relations Contact: Robert Stanislaro, FD, +1-212-850-5600,
robert.stanislaro@fd.com
